Penumbra, Inc. (PEN)
Health Care · Endovascular interventional medical devices / thrombectomy
The world's leading mechanical thrombectomy company enabling rapid, minimally invasive blood clot removal across ischemic stroke, pulmonary embolism, and limb ischemia.
What Penumbra, Inc. does
Penumbra is a leading medical device company specializing in thrombectomy—the mechanical removal of blood clots from blood vessels using minimally invasive endovascular techniques. The company develops and markets innovative technologies for treating ischemic stroke, venous thromboembolism (including pulmonary embolism), acute limb ischemia, and other vascular conditions. Products include computer-assisted vacuum thrombectomy (CAVT) systems and related embolization and neurosurgical devices. The company sells globally through direct sales organizations and distributors, generating $1.4 billion in annual revenue with 17.5% YoY growth.
Themes: ["Thrombectomy / mechanical clot removal","Ischemic stroke treatment","Pulmonary embolism / venous thromboembolism","Acute limb ischemia","Endovascular interventional devices","Neurovascular intervention"]
Fundamentals
- Price$317.95 as of 2026-07-09 close
- Market cap$12.5B as of 2026-07-10
- 1-year return+30.1% as of 2026-07-09 close
- P/E73.15 as of 2026-07-10
- Net margin+11.8% as of 2026-07-10
- Gross margin+67.4% as of 2026-07-10
- ROE+12.3% as of 2026-07-10
- Debt / equity0.02 as of 2026-07-10
- Revenue growth (YoY)+17.3% as of 2026-07-10
- Revenue CAGR (3y)+18.3% SEC XBRL
- Beta0.70 as of 2026-07-10
Key risks (from latest filing)
["Regulatory and reimbursement challenges in international markets could impact growth, particularly in Europe and Asia where market access depends on regulatory approvals and health authority decisions","Competition from larger established medical device companies and newer entrants in the thrombectomy and endovascular space could compress margins and limit market share gains","Product innovation cycle risk—the company's business model depends on introducing next-generation products, and cannibalization of prior generation sales when new products launch could impact short-term revenue recognition"]
Competitors & peers
- Boston Scientific Corporation (BSX)
- Medtronic (MDT)
- Stryker Corporation (SYK)
- Johnson & Johnson / Biosense Webster (JNJ)
- Abbott Vascular (ABT)
- Philips (healthcare imaging and interventional systems)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.